Global venture capital firm New Enterprise Associates has promoted two members of its investing team to General Partner.
– Carmen Chang, a technology investor and Chairman and Head of the firm’s Asia practice, and
– Ali Behbahani, M.D., a healthcare investor focused on the biopharmaceutical and medical devices sectors.
Chang joined NEA in 2012, and was promoted to Chairman and Head of the firm’s Asia practice in 2016. She has been actively involved with the seminal events in China’s technology sector for over 20 years, and since 2012 has been integrally involved with NEA’s activities, partnerships and investments in China. Chang holds a JD from the Stanford Law School and an MA in Modern Chinese History also from Stanford University. Chang is a director of AAC Technologies Holdings, Alien Technology, Drive.ai, Semiconductor Manufacturing International Corporation (SMIC), STX Entertainment, Tuya and Woebot.
Behbahani joined NEA in 2007 and was promoted partner in 2013. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners, as a consultant in business development at The Medicines Company and as a Healthcare Investment Banking Analyst at Lehman Brothers.
Behbahani concurrently earned an MD from The University of Pennsylvania School of Medicine and an MBA from The University of Pennsylvania Wharton School. He serves on the boards of directors of the following companies: Adaptimmune, Arcellx, Cardionomic, CRISPR Therapeutics, CVRx, Genocea, Ivantis, Minerva Surgical, Nevro, Nkarta, Oyster Point Pharma and Solace Therapeutics.